Kailera Therapeutics, Inc.

Kailera Therapeutics has logged zero cyber incidents and zero red-flag 8-K filings over the past 90 days, indicating a stable recent period on those fronts. However, a 90-day window provides limited visibility; our full dataset extends 12 months and incorporates dilution risk scoring, equity financing history, and AI-detected risk signals that shorter timeframes miss. The $49 Report adds shareholder dilution estimates, complete 8-K context, capital structure trends, and machine-flagged early warning indicators across a full year of activity. For biotech investors, that deeper context often reveals risks invisible in quarterly snapshots.